Triapin 5 mg/5 mg, prolonged release tablets

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

Felodipine; Ramipril

Available from:

Primecrown 2010 Limited

ATC code:

C09BB; C09BB05

INN (International Name):

Felodipine; Ramipril

Dosage:

5/5 milligram(s)

Pharmaceutical form:

Prolonged-release tablet

Prescription type:

Product subject to prescription which may be renewed (B)

Therapeutic area:

ACE inhibitors and calcium channel blockers; ramipril and felodipine

Authorization status:

Authorised

Authorization date:

2016-03-11

Patient Information leaflet

                                TRIAPIN
® 5 MG/5 MG PROLONGED RELEASE TABLETS
ramipril/felodipine
xxx000/1
PACKAGE LEAFLET: INFORMATION FOR THE USER
WHAT IS IN THIS LEAFLET
1. What Triapin is and what it is used for
2. What you need to know before you take Triapin
3. How to take Triapin
4. Possible side effects
5. How to store Triapin
6. Contents of the pack and other information
1. WHAT TRIAPIN IS AND WHAT IT IS USED FOR
Triapin 5 mg / 5 mg prolonged release tablets (called also Triapin
tablets in
this leaflet) both contain two medicines called ramipril and
felodipine.

Ramipril
belongs
to
a
group
of
medicines
called
‘angiotensin
converting enzyme inhibitors’ (ACE inhibitors). It works by stopping
the
production of substances that raise blood pressure and makes your
blood vessels relax and widen.

Felodipine
belongs
to
a
group
of
medicines
called
‘calcium
antagonists’. It makes your blood vessels relax and widen. This
helps
to lower your blood pressure
Triapin tablets are used to treat high blood pressure (hypertension).
High blood pressure can mean you are more likely to have problems
such as heart disease, kidney disease and stroke. This medicine
lowers your blood pressure and lowers the risk of these problems.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE TRIAPIN
DO NOT TAKE TRIAPIN TABLETS IF:

You are allergic to:

ramipril or any other ACE inhibitor

felodipine or any other calcium antagonists

any of the other ingredients of this medicine (listed in section 6)

You have ever had a serious allergic reaction called “angioedema”.
The signs include itching, hives (urticaria), red marks on the hands,
feet and throat, swelling of the throat and tongue, swelling around
the
eyes and lips, difficulty breathing and swallowing. Taking this
medicine
may increase the risk of having a more serious attack of this
condition

You have taken or are currently taking sacubitril/valsartan, a
medicine
used to treat a type of long-term (chronic) heart failure in adults

You have heart problems such as heart failure, obstruct
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Triapin 5mg/5 mg, prolonged release tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5 mg of felodipine and 5 mg of ramipril.
Each tablet contains 51.5 mg lactose anhydrous.
Each tablet also contains hydrogenated castor oil.
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Prolonged release tablet
_Product imported from the Italy._
Triapin 5mg/5mg prolonged release tablets are reddish-brown and have
“H/OE” marked on one side and “5” on the
other side.
4 CLINICAL PARTICULARS
As per PA0540/082/002
5 PHARMACOLOGICAL PROPERTIES
As per PA0540/082/002
6 PHARMACEUTICAL PARTICULARS
6.1 LIST OF EXCIPIENTS
Cellulose microcrystalline
Hyprolose
Hypromellose
Iron oxides (E172)
Lactose anhydrous
Macrogol 6000
Hydrogenated castor oil
Maize starch
Paraffin
Propyl gallate
Sodium aluminium silicate
Sodium stearyl fumarate
Titanium dioxide E171
6.2 INCOMPATIBILITIES
Not applicable
6.3 SHELF LIFE
The shelf-life expiry date of this product is the date shown on the
blister and outer carton of the product as marketed in
the country of origin.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_4_
_/_
_0_
_3_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_2_
_1_
_6_
_9_
_7_
_0_
_9_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
6.4 SPECIAL PRECAUTIONS FOR STORAGE
Do not store above 25ºC
6.5 NATURE AND CONTENTS OF CONTAINER
Blisters
28 tablets
6.6 SPECIAL PRECAUTIONS FOR DISPOSAL
No spec
                                
                                Read the complete document
                                
                            

Search alerts related to this product